New Blood Thinner Promises to Stop Clots Without Causing Bleeding

Monday, 17 Jun 2013 12:49 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

British scientists have won early financial backing for a new kind of anticoagulant drug they believe may prevent dangerous blood clots without causing bleeding - a previously unachievable goal.
 
Index Ventures, working with GlaxoSmithKline and Johnson & Johnson via an early-stage biotech fund, said on Monday it was investing $11 million in XO1, a new company set up to develop the experimental medicine.
 
Called ichorcumab, the new drug is still miles from reaching the market - clinical trials are only slated to start within the next two years - but the product may create a stir in a commercially important field, given its unusual properties.
 
It was created by scientists at the University of Cambridge and Addenbrooke's Hospital following the observation of a patient in her 50s whose blood appeared unable to clot but who had no major bleeding problems after a head injury in 2008.
 
The researchers pinpointed her unusual response to a unique antibody, which they went on to synthesise.
 
Currently, anticoagulants are used to reduce the risk of heart attacks and strokes, but doctors have to weigh up carefully their benefits against the danger of triggering uncontrolled bleeding.
 
"This antibody can deliver a high degree of anticoagulation without increased bleeding; we've never seen that before," said Jim Huntingdon, a professor at the Cambridge Institute of Medical and one of the scientists behind the project.
 
Warfarin has been a mainstay of anticoagulation therapy for many years. More recently new drugs have been launched, including Boehringer Ingelheim's Pradaxa, Bayer and J&J's Xarelto, and Pfizer and Bristol-Myers Squibb's Eliquis.
 
The $11 million start-up cash for XO1 comes from a $200 million life sciences fund launched last year by Index in an unusual collaboration with GSK and J&J. The fund aims to invest in companies with just one or two projects - a so-called "asset-centric" approach.
 
Under the three-way deal, the venture capital firm controls all investment decisions and the two drugmakers have no preferential rights to acquire any new drugs, although they do get a useful inside view should they wish to compete for assets.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

With Prostate Cancer, It Helps to Know the Enemy

Friday, 29 Aug 2014 16:47 PM

Prostate cancer patients lacking knowledge about the disease have difficulty making good treatment decisions. This can l . . .

Addiction Fear Keeps Many Cancer Patients in Pain: Study

Friday, 29 Aug 2014 16:42 PM

Fears of opioid abuse and addiction might be keeping patients with advanced cancer from getting enough pain medicine, re . . .

Ebola Drug 100 Percent Effective in Monkeys

Friday, 29 Aug 2014 16:35 PM

An experimental Ebola drug healed all 18 monkeys infected with the deadly virus in a study,boosting hopes that the treat . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved